ArticleThe Journal of investigative dermatology2026
Spatial transcriptomics maps early B-cell and T-cell activation in hidradenitis suppurativa.
Article in The Journal of investigative dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Type 17 T-cell subset divergence in hidradenitis suppurativa versus psoriasis: a comparative single-cell transcriptomic analysis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hidradenitis suppurativa is a chronic, debilitating inflammatory skin disease that progresses from superficial nodules in early stages to dermal tunnels, tertiary lymphoid structures, and fibrosis in advanced lesions. Interplays between dermal tunnel keratinocytes, tertiary lymphoid structures, and fibroblasts promote pathogenic T-cell and B-cell inflammation in late-stage disease. However, whether these immune activations sequentially precede or follow late-stage structure formation is unclear. To delineate the temporal sequence of immune activation, we integrated spatial and single-cell transcriptomic analyses of early- and late-stage hidradenitis suppurativa and compared them with those of acne conglobata and psoriasis. Spatial transcriptomics of 156 regions of interest revealed robust dermal immune activation in early-stage hidradenitis suppurativa, including B-cell enrichment, type 17 T-cell pathway activation, and neutrophilic infiltration, occurring prior to tunnel or tertiary lymphoid structure formation. Single-cell RNA sequencing confirmed early plasma cell expansion and identified multifunctional B cells expressing proinflammatory cytokines, antigen-presentation machinery, and Igs. Notably, T cells rather than fibroblasts were the predominant producers of the B-cell chemoattractant CXCL13 in early lesions. Together, these findings demonstrate that hidradenitis suppurativa exhibits early and sustained immune activation that precedes dermal remodeling, underscoring the aggressive nature from its onset and suggesting that early therapeutic targeting of the type 17 T-cell axis and B-cell-mediated inflammation may help prevent disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.